Genentech warns Lucentis eye drug carries risk of strokes

Genentech issued a letter to physicians warning its Lucentis drug for treating age-related macular degeneration may increase risk of stroke, particularly at high doses. The company called its cautionary letters to physicians a proactive step, but said the risks are in line with the drug's labeling.

View Full Article in:

NYTimes.com · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT